SecBot SecBot
SECBOTREPLAY Home › Report › GH

GH · The District of Delaware denied Guardant Health's post-trial motions in…

Guardant Health, Inc. · COURT-RULING filed Jun 15, 2026 at 20:00 ET

At the news

BEARISHIMPACT 7/10

COURT-RULING filed Jun 15, 2026 at 20:00 ET

The District of Delaware denied Guardant Health's post-trial motions in a patent infringement case brought by TwinStrand Biosciences and UW. The jury's 2023 verdict of willful infringement on two patents covering DNA sequencing technology stands, with $83.4M in damages based on a 6% royalty on $1.39B revenue base. The court denied enhanced damages and attorney fees but granted ongoing royalties at the same 6% rate plus supplemental damages and pre/post-judgment interest. Guardant's products and services (including Guardant360, Companion, Explore) were found to infringe.

  • Jury awarded $83.4M in reasonable royalty damages (6% on $1.39B base including $106M services revenue) for willful infringement of claims on patented duplex consensus sequencing technology
  • Court denied Guardant's motions for JMOL, new trial, and Rule 60(b) relief on all grounds, infringement findings across products (Guardant360) and services (Companion, Explore) are upheld
  • Ongoing royalty set at 6% for adjudicated products post-verdict, plus supplemental damages at 6% for sales July 2023–Feb 2024, and pre-judgment interest at prime rate compounded quarterly
  • Court declined to enhance damages under Read factors, case was close, no egregious litigation misconduct or concealment, but willfulness verdict was supported by evidence

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access